XML 34 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Operating activities:    
Net loss $ (62,428) $ (39,052)
Adjustments to reconcile net loss to cash used in operating activities:    
Acquired in-process research and development 23,049  
Depreciation and amortization 118 72
Stock-based compensation 4,841 4,410
Net unrealized loss on foreign currency transactions 260 240
Amortization of term loan discount and issuance costs 203 237
Amortization of investments, net 127 314
Deferred revenue 25,078  
Changes in operating assets and liabilities:    
Accounts receivable (2,838)  
Prepaid expenses and other current assets (158) 214
Accounts payable 2,508 (1,578)
Accrued expenses 432 3,099
Right-of-use assets and lease liabilities, net 75 (37)
Net cash used in operating activities (8,733) (32,081)
Investing activities:    
Purchases of property and equipment (279) (57)
Purchases of short-term investments (14,962) (32,992)
Maturities of short-term investments 33,225 60,455
Net cash provided by investing activities 18,684 27,406
Financing activities:    
Principal repayments on note payable (1,429)  
Proceeds from exercise of stock options 0 891
Proceeds from ESPP purchases 214 261
Net cash (used in) provided by financing activities (1,215) 31,061
Effect of exchange rate changes on cash and cash equivalents 5 (2)
Net increase in cash and cash equivalents 8,741 26,384
Cash and cash equivalents at beginning of period 50,366 23,982
Cash and cash equivalents at end of period 59,107 50,366
Supplemental cash flow information:    
Cash paid for interest 847 836
Right-of-use assets obtained in exchange for lease obligations 0 1,759
Amounts included in accounts payable for purchases of property and equipment   14
Bioniz    
Investing activities:    
Cash acquired in Bioniz acquisition 700  
Supplemental cash flow information:    
Fair value of Bioniz assets acquired 23,049  
Bioniz net liabilities assumed 507  
Issuance of common stock for Bioniz acquisition $ (22,542)  
Follow-on Offering    
Financing activities:    
Proceeds from issuance of common stock from follow-on offering, net of issuance costs   $ 29,909